1776 – Newborn bloodspot screening for mucopolysaccharidosis Type II (MPS II; Hunter syndrome)

Page last updated: 21 October 2024

Application Detail

Description of Medical Service

It is proposed that a screening test for mucopolysaccharidosis Type II (MPS II) be added to existing newborn bloodspot screening programs in Australia. Screening will be of newborn babies within 48-72 hours of birth. The initial test consists of collecting blood samples from all newborns via a heel-prick onto filter paper cards, and sending these to a laboratory for testing. When a newborn is diagnosed with MPS II, it is proposed that cascade testing is offered to biological mothers and siblings.

Description of Medical Condition

MPS II, also known as Hunter syndrome, is a type of lysosomal storage disease. It is a rare, inherited genetic condition that mainly occurs in boys (X-linked), where variations occur in the IDS gene. In MPS II, an enzyme called iduronate 2-sulfatase doesn’t work properly. This enzyme is responsible for breaking down complex sugar molecules called glycosaminoglycans (GAGs) that are stored in small compartments of cells called lysosomes. This decreased activity of the iduronate 2-sulfatase enzyme results in toxic build-up of dermatan sulphate and heparan sulphate in multiple organs of the body. This leads to development of symptoms that includes an enlarged liver and spleen, umbilical or inguinal hernia, hearing loss, narrowing of the spinal canal compressing the spinal cord, and heart valve abnormalities. Severity of symptoms and age of onset vary between individuals. The most severe form of disease is characterised by earlier onset of symptoms, more rapid disease progression and neuronopathic involvement, leading to symptoms of significant neurological impairment, including cognitive disability and behavioural problems.

Reason for Application

Inclusion in NBS

Medical Service Type

Investigative technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Summary and PICO Set

Application Summary (PDF 409 KB)
Application Summary (Word 34 KB)

PICO Set 1 (PDF 906 KB)
PICO Set 1 (Word 285 KB)

PICO Set 2 (PDF 1201 KB)
PICO Set 2 (Word 333 KB)

Consultation Survey

Consultation Survey

PASC Consultation
PASC consultation closed 15 March 2024

MSAC Consultation
MSAC consultation closes Friday 14 February 2025

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

PICO Confirmation (PDF 1094 KB)
PICO Confirmation (Word 624 KB)

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

18–19 April 2024

ESC

13-14 February 2025

MSAC

3-4 April 2025